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Objective: Although fibrinogen- and thrombin-impregnated collagen (TachoSil;
Takeda GmbH, Linz, Austria) can be applied to prevent air leakage, the impact of
its use on lung healing is unknown. Therefore, we histologically evaluated the
long-term healing process associated with the use of TachoSil to prevent air
leakage in a canine model.
Methods: Via left thoracotomy, visceral pleural defects of 10 3 10 mm were
created on each lung lobe of female beagles. After air leakage was confirmed,
each pleural defect was covered with TachoSil. The repair sites were histological-
ly evaluated on postoperative days 0, 4, 7, 14, 28, and 56.
Results: All animals survived, and none developed pneumothorax. Histological-
ly, inflammatory cells infiltrated the TachoSil from the pleural defect, and pleural
mesothelium comprised the regenerated outermost layer of the TachoSil soon af-
ter the surgery. Inflammatory cells, myofibroblasts, and neovascular vessels sub-
sequently spread over the entire TachoSil. The number of inflammatory cells
decreased, and myofibroblast and neovascular vessels replaced the entire Tacho-
Sil. In addition, the elastic layer started to regenerate from both edges and
completely repaired the pleural defect. The lung parenchyma around the pleural
defects was not influenced throughout the observational period, because these
healing processes occurred only inside the TachoSil.
Conclusions: TachoSil provided a mechanical scaffold on which healing could
proceed, followed by biodegradation over the long term. TachoSil safely repaired
the pleural defects without affecting lung parenchyma. (J Thorac Cardiovasc Surg
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TachoSil.Central Message
TachoSil safely prevents air leakagewithout affecting lung pa-
renchyma. It provided amechanical scaffold onwhich healing
could proceed, followed by biodegradation over the long term.Perspective
AlthoughTachoSil can be applied toprevent air leakage, the
impact of its use on lung healing is unknown. This study his-
tologically showed the long-term healing processes associ-
ated with TachoSil, which is used to prevent air leakage.
TachoSil provided a mechanical scaffold on which healing
could proceed, with subsequent replacement by myofibro-
blasts and neovascular vessels. TachoSil safely prevented
air leakage without negatively affecting the lung paren-
chyma and without leaving remaining foreign material.See Editorial Commentary page 989.See Editorial page 960.Postoperative air leakage is a frequent complication of pul-
monary resection.1,2 Persistent air leakage has negative
consequences on morbidity, culminating in a lengthy
hospitalization with negative economic effects and delayed
adjuvant treatment.3-7 Therefore, a safe and effective
procedure is required to prevent and control air leakage.TachoSil (Takeda GmbH, Linz, Austria) has been suc-
cessfully used to reduce the prevalence of the complication
of air leakage after pulmonary resection.2,3,8-11 However,
the impact of TachoSil use on lung healing is unknown.
Therefore, we histologically evaluated the long-term heal-
ing processes associated with the use of TachoSil to prevent
air leakage in a canine model.MATERIALS AND METHODS
Animals and Initial Operation
Female beagles (Kitayama Labes Co Ltd, Nagano, Japan) were preanes-
thetized with ketamine (10 mg/kg) and atropine sulfate (0.5 mg), intubated
under general anesthesia (5 mg/kg propofol intravenously; 1 mg/kg succi-
nylcholine intravenously), and placed under controlled ventilation. Cefazo-
lin (1 g) was intraoperatively administered. Anesthesia was maintained by
periodic injections of propofol and succinylcholine.
Abbreviations and Acronyms
a-SMA ¼ a-smooth muscle actin
POD ¼ postoperative day
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Animals were placed in the right lateral position for a left thoracotomy.
Visceral pleural defects of 103 10 mm were created on the side of the chest
wall, the mediastxinal side, and the interlobar side by sharp dissection. We
dissected lung parenchyma to the depths confirming bleeding and air leakage
from the created pleural defect. Constrictionwas applied if needed, but cautery
was not. TachoSil was applied to cover each pleural defect with an overlap of
more than 5 mm and held against the lung tissue for 5 minutes (Figure 1). We
macroscopically confirmed that TachoSil firmly attached to the defect. No
visible air leakage was confirmed. The chest wall was closed after air evacua-
tion by chest tube. After no air leakage was observed, the chest tube was
removed before the dogs were extubated. The animals were returned to their
cages after being injected intramuscularly with ketoprofen (1 mg/kg).
Animals were euthanized by a pentobarbital overdose on postoperative
days (PODs) 0, 4, 7, 14, 28, and 56. Six dogs were used; 1 was killed on
each POD. Three or 4 pleural defects were created in 1 dog for each
time point. Thoracotomy in a different intercostal space was performed
to macroscopically evaluate postoperative pleural adhesions. The left
lung and the surrounding adherent tissue were harvested for each lobe
except for the case processed on POD 14, in which en bloc resection was
performed because of interlobar adhesion.
Histologic Findings
Specimenswere fixed in 10% buffered formalin, and the pleura covered by
TachoSil was serially cut into 5mm–thick slices. BecauseTachoSil was not de-
tected bymacroscopic findings on POD56, the entire lobewas serially cut into
5 mm–thick sections and then all paraffin-embedded sections were evaluated
by hematoxylin–eosin staining. Pleural defects and the proliferation of myofi-
broblasts and neovascular vessels were respectively assessed by staining the
sections with Elastica van Gieson, a-smooth muscle actin (a-SMA), and
CD31. The expression levels of each cell were defined as follows:
1þ¼mean low levels, 2þ¼ intermediate levels, and 3þ¼ high levels of in-
flammatory cells, myofibroblasts, and neovascular vessels. The Ethics Com-
mittee of Hiroshima University approved the study protocol, and laboratory
animalcareproceeded according to theguidelines for laboratoryanimalcare.12
RESULTS
Macroscopic Findings
A total of 20 TachoSil patches (3-4 per dog) were applied
to pleural defects in the dogs. All dogs survived without se-
vere complications throughout the observation period.
Further, all TachoSil patches were attached to the lung
parenchymal surface. Extensive inflammation or pneumo-
thorax was not observed at the time of sacrifice (Table 1).
Two adhesions (10%) were found in the pleura covered
by TachoSil: 1 each in the interlobar and mediastinal pleura
on PODs 7 and 14, respectively. TachoSil was macroscopi-
cally detectable until POD 28 and only microscopically
detectable on POD 56.
Microscopic Findings
Pleural defects were confirmed as spaces caused by air
leakage on POD 0 (Figure 2, A) and as the loss of the elastic
layer on Elastica van Gieson–stained sections (Figure 3).The Journal of Thoracic and CaThe time-dependent changes of each of the cells are sum-
marized in Table 1. The mesothelium had formed and
covered the outermost layer of the TachoSil after POD 4
(Figure 2, N). Inflammatory cells such as lymphocytes
and neutrophils initially infiltrated the space, which
became filled with these cells and blood cells on POD 4
(Figure 2, B). Subsequently, inflammatory cells spread
widely to the TachoSil from POD 7 (Figure 2, C) to 28
(Figure 2, E), but the cell numbers had decreased by
POD 56 (Figure 2, F). However, the myofibroblasts and
neovascular vessels exhibited histologic characteristics
that differed from those of the inflammatory cells. The my-
ofibroblasts and neovascular vessels formed in the Tacho-
Sil around the pleural defects on POD 7 (Figure 4, C
and I), which was after the inflammatory cells were first
observed, and increased progressively from POD 7 to 28
(Figure 4, E andK). Finally, the myofibroblasts and neovas-
cular vessels remained in the TachoSil, occupying the
entire TachoSil on POD 56 (Figure 4, F and L). In addition,
by POD 14, the pleural defects were confirmed to be loss of
the elastic layer (Figure 3, A-D). However, elastic layer
regeneration originated from both edges, and pleural de-
fects started to decrease on POD 28 (Figure 3, E). The
pleural defect was completely repaired by POD 56
(Figure 3, F). Because these healing processes occurred
only inside the TachoSil, the lung parenchyma around the
pleural defects was not influenced throughout the observa-
tional period.
DISCUSSION
This study histologically demonstrated the long-term
healing processes associated with TachoSil, which is used
to prevent air leakage. TachoSil safely repaired pleural de-
fects to prevent air leaks without negatively affecting the
lung parenchyma and without leaving remaining foreign
material. TachoSil provided a mechanical scaffold on which
healing could proceed, followed by biodegradation over the
long term.
Because 90% of air leaks resolve by POD 7,13 we
included 2 observation end points in this study: prevention
of air leakage in the early postoperative period (PODs 0, 4,
and 7) and assessment of possible adverse effects in the late
period (PODs 14, 28, and 56). The pleural spaces respon-
sible for air leakage were replaced with inflammatory cells
and blood cells on POD 4, and these changes became pro-
nounced on POD 7. In addition, the pleural area around
the defects adhered to the TachoSil, and these histologic
changes were responsible for prevention of air leakage. A
previous study14 demonstrated the histologic changes asso-
ciated with the use of fibrin glue-coated collagen fleece to
repair pleural defects until POD 7, and these findings
were consistent with our results. However, the changes in
the TachoSil and their long-term effects on the lung paren-
chyma have remained unclear. The present study showedrdiovascular Surgery c Volume 149, Number 4 983
FIGURE 1. Pleural defects and TachoSil (Takeda GmbH, Linz, Austria) cover. Pleural defects of 10 3 10 mm were created by sharp dissection (A). Ta-
choSil covers pleural defect with overlap greater than 5 mm (B). TachoSil collagen patch coated with human fibrinogen and thrombin.
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term without negatively affecting the lung parenchyma. Af-
ter inflammatory cells infiltrated the pleural defects, myofi-
broblasts and neovascular vessels formed and spread over
the entire TachoSil with the inflammatory cells. Finally,
the number of inflammatory cells decreased, and the myofi-
broblasts and neovascular vessels replaced the TachoSil.
The TachoSil did not remain as a foreign material. Adverse
effects on the lung parenchyma were not found because
these healing processes occurred only inside the TachoSil.
In addition, few adhesions were detected in the area
covered by the TachoSil, and several possibilities can be
proposed to explain this finding. First, although an inflam-
matory reaction occurred within the TachoSil, it did not
occur beyond the TachoSil. Second, the outermost layer
of the TachoSil became covered with 1 layer of mesothe-
lium from POD 4, and a rapidly developing mesothelium
could prevent adhesions. A relationship between TachoSil
and adhesions has been identified in intra-abdominal,15
pericardial,16 and gynecologic17 regions. To our knowl-
edge, pleural adhesions have been prevented only in a few
studies in rat models.18,19 One study in a rat model19
showed that the pleural defects that were healed by the
use of hemostatic fleece became covered by regular meso-
thelium, and the fleece prevented the development of
pleural adhesions. Further, hemostatic fleece promoted
rapid mesothelial recovery and reduced plasminogenTABLE 1. Surgical and postoperative pathologic findings of TachoSil (Tak
POD 0 4
No. of TachoSil patches for 1 dog n ¼ 3 n ¼ 4
Adhesion 0 0
Macroscopic confirmation þ þ
Regeneration of mesothelium  þ
Inflammatory cells  þ
Myofibroblasts  þ
Neovascular vessels  þ
Regeneration of elastic layers  
POD, Postoperative day.
984 The Journal of Thoracic and Cardiovascular Surgactivator inhibitor-1 levels, leading to the biochemical inhi-
bition of adhesion formation.18
The myofibroblasts and elastic layer comprised an impor-
tant part of the healing process. Myofibroblasts regulate the
remodeling of connective tissue by combining the extracel-
lular matrix-synthesizing features of fibroblasts with the
cytoskeletal characteristics of contractile smooth muscle
cells.20 Myofibroblasts that are characterized by the expres-
sion of a-SMA represent key players in the physiologic
reconstruction of connective tissue after injury and in gener-
ating the pathologic tissue deformations that characterize
fibrosis.20-24 Our findings demonstrate that similar
processes occurred during the healing of pleural defects by
TachoSil because the a-SMA–positive layer, which
indicates the presence of myofibroblasts, gradually
thickened from POD 7 to 56 inside the TachoSil.
Excessive and persistent myofibroblast activities transform
beneficial tissue repair into the detrimental tissue
deformities characteristic of organ fibrosis.20 However, the
myofibroblasts acted only inside the TachoSil, and not in
the lung parenchyma, without showing evidence of exces-
sive activity. The elastic layer was also involved in the heal-
ing procedure. This study demonstrated that the elastic layer
regenerated from both edges on POD 28, with the pleural de-
fects disappearing by POD 56. We previously reported that
the processes associated with the TachoComb (Takeda
GmbH) during healing of an injured pulmonary arteryeda GmbH, Linz, Austria)
7 14 28 56
n ¼ 3 n ¼ 4 n ¼ 3 n ¼ 3
1 1 0 0
þ þ þ 
þ þ þ þ
3þ 3þ 2þ 
þ 2þ 3þ 3þ
2þ 2þ 2þ 2þ
  þ þ
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FIGURE 2. Postoperative hematoxylin–eosin staining. Postoperative hematoxylin–eosin staining visualized using loupe (A-F). Around pleural defects
(G-L), magnification,3100. Outermost layer of TachoSil (M-R), magnification,3100.Arrowheads shows both edges of elastic layer (confirmed by Elastica
van Gieson staining in Figure 3). Inflammatory infiltration was noted immediately on POD 4, increased progressively from POD 4 to 28, and was resolved by
POD 56. In addition, mesothelium (arrow) covers the outermost layer of TachoSil on POD 4 (N). TachoSil collagen patch coated with human fibrinogen and
thrombin. POD, Postoperative day; TS, TachoSil.
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layer and the TachoComb from both edges.25 The present
findings were similar, although the reason for regeneration
of the elastic layer remains unknown.
Study Limitations
First, the canine model differed from the condition that
is observed in a clinical setting. Clinically, postoperativeThe Journal of Thoracic and Caair leakage often occurs in patients with emphysematous
or fibrotic patterns, whereas the lung was normal in the
canine model used in this study. In addition, the pleural de-
fects were small and created without removal of the lung.
Thus, the pleural defects may have healed relatively
quickly with complete lung reexpansion and apposition
of the lung to the surrounding tissues. Further studies are
required in a setting that is more similar to that observedrdiovascular Surgery c Volume 149, Number 4 985
FIGURE 3. Findings of Elastica van Gieson staining. Sections stained with Elastica van Gieson visualized using a loupe (A-F). Arrow and arrowheads
show elastic layer and both edges of it, respectively. Elastic layer started to regenerate from both edges on POD 28 (E) and exhibited repair by POD 56
(F). POD, Postoperative day.
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group, and we assessed only a single animal at each time
point. However, although the results in this study were
not adequate for performing a quantitative analysis,
similar results were obtained in 3 to 4 tissues per time
point. Given this finding, we presumed that including addi-
tional animals would not greatly change the overall results,
so we minimized the number of dogs used from the stand-
point of animal welfare. These limitations should be
considered when interpreting the results and conclusions
of this study.986 The Journal of Thoracic and Cardiovascular SurgCONCLUSIONS
Our study histologically demonstrated the long-term
healing processes associated with TachoSil, which is
used to prevent air leakage. TachoSil safely repaired
pleural defects without negatively affecting the lung pa-
renchyma and without leaving remaining foreign
material.
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FIGURE 4. Staining of myofibroblasts and neovascular vessels. Sections stained with a-SMA (A-F) and CD31 visualized using a loupe (G-L) and CD31
stain at3100 magnification (M-R). Myofibroblasts and neovascular vessels have formed and widely spread throughout TachoSil from POD 7 to 28, occu-
pying the entire TachoSil on POD 56. TachoSil collagen patch coated with human fibrinogen and thrombin. a-SMA, a-Smooth muscle actin; POD,
postoperative day.
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